Karyopharm Therapeutics Inc
2 clinical trials · 2 recruiting · INDUSTRY
Trials by Karyopharm Therapeutics Inc
RECRUITINGPhase 2 / Phase 3NCT04442022
A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With...
The purpose of this Phase 2/3 study is to evaluate efficacy and safety of the combination of selinexor and R-GDP (SR-GDP) in patients with RR DLBCL who are not intended to receive...
Sponsor: Karyopharm Therapeutics IncEnrolling: 50120 locations
Relapsed/Refractory Diffuse Large B-cell Lymphoma
RECRUITINGPhase 1 / Phase 2NCT02343042
Selinexor and Backbone Treatments of Multiple Myeloma Patients
This study will independently assess the efficacy and safety of 11 combination therapies in 12 arms, in dose-escalation/-evaluation and expansion phases, for the treatment of...
Sponsor: Karyopharm Therapeutics IncEnrolling: 30020 locations
Multiple Myeloma